Published in Exp Neurol on June 01, 2005
Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol (2007) 2.71
Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol (2007) 2.36
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics (2009) 2.36
Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci (2006) 2.15
Lewy bodies. Proc Natl Acad Sci U S A (2006) 2.15
Studies on free radicals, antioxidants, and co-factors. Clin Interv Aging (2007) 2.09
Antioxidants in central nervous system diseases: preclinical promise and translational challenges. J Alzheimers Dis (2008) 1.88
T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening? Trends Immunol (2009) 1.78
Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain (2008) 1.77
Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's disease. Exp Neurol (2012) 1.60
Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. Clin Neurosci Res (2006) 1.50
Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat Rev Neurosci (2011) 1.45
Butein provides neuroprotective and anti-neuroinflammatory effects through Nrf2/ARE-dependent haem oxygenase 1 expression by activating the PI3K/Akt pathway. Br J Pharmacol (2016) 1.43
Mechanisms of methamphetamine-induced dopaminergic neurotoxicity. AAPS J (2006) 1.40
Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One (2010) 1.29
Parkin-mediated selective mitochondrial autophagy, mitophagy: Parkin purges damaged organelles from the vital mitochondrial network. FEBS Lett (2010) 1.24
Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog Neurobiol (2013) 1.20
Effects of hydrogen sulfide-releasing L-DOPA derivatives on glial activation: potential for treating Parkinson disease. J Biol Chem (2010) 1.20
Pharmacological inhibition of neuronal NADPH oxidase protects against 1-methyl-4-phenylpyridinium (MPP+)-induced oxidative stress and apoptosis in mesencephalic dopaminergic neuronal cells. Neurotoxicology (2007) 1.20
A Wnt1 regulated Frizzled-1/β-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotection. Mol Neurodegener (2011) 1.13
Dexamethasone inhibits the Nox-dependent ROS production via suppression of MKP-1-dependent MAPK pathways in activated microglia. BMC Neurosci (2011) 1.09
The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection. J Neuroinflammation (2008) 1.06
Complexity of dopamine metabolism. Cell Commun Signal (2013) 1.06
JNK3 mediates paraquat- and rotenone-induced dopaminergic neuron death. J Neuropathol Exp Neurol (2010) 1.04
Systemic administration of lipopolysaccharide induces cyclooxygenase-2 immunoreactivity in endothelium and increases microglia in the mouse hippocampus. Cell Mol Neurobiol (2009) 1.04
Age-dependent decrease and alternative splicing of methionine synthase mRNA in human cerebral cortex and an accelerated decrease in autism. PLoS One (2013) 1.02
Neuroprotective Mechanisms of PPARδ: Modulation of Oxidative Stress and Inflammatory Processes. PPAR Res (2011) 1.01
Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease. PLoS One (2012) 0.97
Mitochondria and energetic depression in cell pathophysiology. Int J Mol Sci (2009) 0.95
Formation of dopamine adducts derived from brain polyunsaturated fatty acids: mechanism for Parkinson disease. J Biol Chem (2008) 0.94
Age-related changes in dopamine transporters and accumulation of 3-nitrotyrosine in rhesus monkey midbrain dopamine neurons: relevance in selective neuronal vulnerability to degeneration. Eur J Neurosci (2008) 0.90
Neuroprotection by marine-derived compound, 11-dehydrosinulariolide, in an in vitro Parkinson's model: a promising candidate for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.89
Novel cell death signaling pathways in neurotoxicity models of dopaminergic degeneration: relevance to oxidative stress and neuroinflammation in Parkinson's disease. Neurotoxicology (2009) 0.88
PINK1 Deficiency Enhances Inflammatory Cytokine Release from Acutely Prepared Brain Slices. Exp Neurobiol (2013) 0.87
Molecular events underlying Parkinson's disease - an interwoven tapestry. Front Neurol (2013) 0.86
PEP-1-PON1 protein regulates inflammatory response in raw 264.7 macrophages and ameliorates inflammation in a TPA-induced animal model. PLoS One (2014) 0.86
Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease. PLoS One (2011) 0.85
Spinal astrogliosis in pain models: cause and effects. Cell Mol Neurobiol (2009) 0.85
Age-related learning and memory deficits in rats: role of altered brain neurotransmitters, acetylcholinesterase activity and changes in antioxidant defense system. Age (Dordr) (2014) 0.85
Transduced Tat-DJ-1 protein protects against oxidative stress-induced SH-SY5Y cell death and Parkinson disease in a mouse model. Mol Cells (2012) 0.84
The influence of cannabinoids on generic traits of neurodegeneration. Br J Pharmacol (2014) 0.84
Association of fibrinogen with Parkinson disease in elderly Japanese-American men: a prospective study. Neuroepidemiology (2009) 0.84
Drosophila DJ-1 decreases neural sensitivity to stress by negatively regulating Daxx-like protein through dFOXO. PLoS Genet (2013) 0.83
Gng12 is a novel negative regulator of LPS-induced inflammation in the microglial cell line BV-2. Inflamm Res (2009) 0.83
Autologous transplants of Adipose-Derived Adult Stromal (ADAS) cells afford dopaminergic neuroprotection in a model of Parkinson's disease. Exp Neurol (2007) 0.83
Protection of MPTP-induced neuroinflammation and neurodegeneration by Pycnogenol. Neurochem Int (2013) 0.82
Intrathecal infusion of hydrogen-rich normal saline attenuates neuropathic pain via inhibition of activation of spinal astrocytes and microglia in rats. PLoS One (2014) 0.82
Deletion of caspase-8 in mouse myeloid cells blocks microglia pro-inflammatory activation and confers protection in MPTP neurodegeneration model. Aging (Albany NY) (2015) 0.81
A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP. Br J Pharmacol (2012) 0.81
Mitochondrial cell death control in familial Parkinson disease. PLoS Biol (2007) 0.81
Brain mediators of systemic oxidative stress on perceptual impairments in Parkinson's disease. J Transl Med (2015) 0.81
Beneficial Effect of Vitamin E in Rotenone Induced Model of PD: Behavioural, Neurochemical and Biochemical Study. Exp Neurobiol (2013) 0.81
Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum. Neuroscience (2008) 0.80
Glial cell-line derived neurotrophic factor (GDNF) replacement attenuates motor impairments and nigrostriatal dopamine deficits in 12-month-old mice with a partial deletion of GDNF. Pharmacol Biochem Behav (2013) 0.80
Recent advances on the neuroprotective potential of antioxidants in experimental models of Parkinson's disease. Int J Mol Sci (2012) 0.80
RING finger protein 11 (RNF11) modulates susceptibility to 6-OHDA-induced nigral degeneration and behavioral deficits through NF-κB signaling in dopaminergic cells. Neurobiol Dis (2013) 0.80
Association Between Autonomic Impairment and Structural Deficit in Parkinson Disease. Medicine (Baltimore) (2016) 0.80
The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's disease. Int J Mol Sci (2011) 0.80
Effect of parasitic infection on dopamine biosynthesis in dopaminergic cells. Neuroscience (2015) 0.79
Bid signal pathway components are identified in the temporal cortex with Parkinson disease. Neurology (2012) 0.78
Specific changes of serum proteins in Parkinson's disease patients. PLoS One (2014) 0.78
Perturbations in dopamine synthesis lead to discrete physiological effects and impact oxidative stress response in Drosophila. J Insect Physiol (2015) 0.78
Neuroprotective Properties of the Standardized Extract from Camellia sinensis (Green Tea) and Its Main Bioactive Components, Epicatechin and Epigallocatechin Gallate, in the 6-OHDA Model of Parkinson's Disease. Evid Based Complement Alternat Med (2015) 0.77
The degenerating substantia nigra as a susceptible region for gene transfer-mediated inflammation. Parkinsons Dis (2011) 0.77
Selective protection of the cerebellum against intracerebroventricular LPS is mediated by local melatonin synthesis. Brain Struct Funct (2013) 0.77
Short-term effects of an endotoxin on substantia nigra dopamine neurons. Brain Res (2014) 0.77
Zhichan powder regulates nigrostriatal dopamine synthesis and metabolism in Parkinson's disease rats. Neural Regen Res (2012) 0.77
Involvement of Heme Oxygenase-1 Induction in the Cytoprotective and Immunomodulatory Activities of Viola patrinii in Murine Hippocampal and Microglia Cells. Evid Based Complement Alternat Med (2012) 0.77
Low-Dose Homocystine Enhances Proliferation and Migration of Bv2 Microglia Cells. Cell Mol Neurobiol (2016) 0.77
Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's Disease. Front Neurosci (2016) 0.76
Effects of Oxidative Stress and Testosterone on Pro-Inflammatory Signaling in a Female Rat Dopaminergic Neuronal Cell Line. Endocrinology (2016) 0.76
Protective Effects of Streblus asper Leaf Extract on H2O2-Induced ROS in SK-N-SH Cells and MPTP-Induced Parkinson's Disease-Like Symptoms in C57BL/6 Mouse. Evid Based Complement Alternat Med (2015) 0.76
Apocynin prevents mitochondrial burdens, microglial activation, and pro-apoptosis induced by a toxic dose of methamphetamine in the striatum of mice via inhibition of p47phox activation by ERK. J Neuroinflammation (2016) 0.76
Having a Coffee Break: The Impact of Caffeine Consumption on Microglia-Mediated Inflammation in Neurodegenerative Diseases. Mediators Inflamm (2017) 0.75
Plasma DNA Mediate Autonomic Dysfunctions and White Matter Injuries in Patients with Parkinson's Disease. Oxid Med Cell Longev (2017) 0.75
The Parkinson Disease gene SNCA: Evolutionary and structural insights with pathological implication. Sci Rep (2016) 0.75
Reversal of oxidative stress-induced apoptosis in T and B lymphocytes by Coenzyme Q10 (CoQ10). Am J Clin Exp Immunol (2016) 0.75
KCHO-1, a Novel Antineuroinflammatory Agent, Inhibits Lipopolysaccharide-Induced Neuroinflammatory Responses through Nrf2-Mediated Heme Oxygenase-1 Expression in Mouse BV2 Microglia Cells. Evid Based Complement Alternat Med (2014) 0.75
Post-translational Activation of Glutamate Cysteine Ligase with Dimercaprol: A NOVEL MECHANISM OF INHIBITING NEUROINFLAMMATION IN VITRO. J Biol Chem (2017) 0.75
Protective Mechanisms of Flavonoids in Parkinson's Disease. Oxid Med Cell Longev (2015) 0.75
A Novel Immunosuppressor, (5R)-5-Hydroxytriptolide, Alleviates Movement Disorder and Neuroinflammation in a 6-OHDA Hemiparkinsonian Rat Model. Aging Dis (2017) 0.75
Loss of Parkin reduces inflammatory arthritis by inhibiting p53 degradation. Redox Biol (2017) 0.75
Associations among Cognitive Functions, Plasma DNA, and White Matter Integrity in Patients with Early-Onset Parkinson's Disease. Front Neurosci (2017) 0.75
Parkinson's disease: genetics and beyond. Curr Neuropharmacol (2007) 0.75
SUR1 Receptor Interaction with Hesperidin and Linarin Predicts Possible Mechanisms of Action of Valeriana officinalis in Parkinson. Front Aging Neurosci (2016) 0.75
Pathological correlations between traumatic brain injury and chronic neurodegenerative diseases. Transl Neurodegener (2017) 0.75
Tetramethylpyrazine Ameliorates Rotenone-Induced Parkinson's Disease in Rats: Involvement of Its Anti-Inflammatory and Anti-Apoptotic Actions. Mol Neurobiol (2016) 0.75
Challenges in antimalarial drug discovery. Future Med Chem (2011) 1.17
Requirement of a dopaminergic neuronal phenotype for toxicity of low concentrations of 1-methyl-4-phenylpyridinium to human cells. Toxicol Appl Pharmacol (2009) 1.09
Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels. Brain Res (2007) 1.05
A randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of single enantiomer (+)-mefloquine compared with racemic mefloquine in healthy persons. Am J Trop Med Hyg (2010) 0.99
Specific modulation of astrocyte inflammation by inhibition of mixed lineage kinases with CEP-1347. J Immunol (2004) 0.94
HIF prolyl hydroxylase inhibition increases cell viability and potentiates dopamine release in dopaminergic cells. J Neurochem (2010) 0.93
Targeted expression of BCL-2 attenuates MPP+ but not 6-OHDA induced cell death in dopaminergic neurons. Neurobiol Dis (2003) 0.90
Inflammation in Parkinson's disease: causative or epiphenomenal? Subcell Biochem (2007) 0.87
Repositioning: the fast track to new anti-malarial medicines? Malar J (2014) 0.83
In vitro and in vivo activity of solithromycin (CEM-101) against Plasmodium species. Antimicrob Agents Chemother (2011) 0.81
In vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium models. Drug Des Devel Ther (2013) 0.79
[Free radicals and ailing proteins--the culprits behind Parkinson disease?]. Lakartidningen (2003) 0.75